Kathleen Sebelius
Known title: DirectorCIK: 0001654316
Kathleen Sebelius's purchase track record
Kathleen Sebelius has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2026 | HUMA | $50K | -29.7% | pending | — |
| 4/8/2025 | HUMA | $66K | +123.5% | +43.0% | +34.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HUMA | ▲ Buy | Open Market | 56,818 | $50K | 5/19/2026 | View on chart |
| HUMA | ▲ Buy | Open Market | 50,000 | $66K | 4/8/2025 | View on chart |
| HUMA | ▲ Buy | Option Exercise | 4,521 | $20K | 9/10/2024 | View on chart |
| HUMA | ▼ Sell | Open Market | 3,634 | $20K | 9/10/2024 | View on chart |
| HUMA | ▲ Buy | Option Exercise | 2,479 | $8K | 9/10/2024 | View on chart |
| HUMA | ▼ Sell | Open Market | 1,548 | $8K | 9/10/2024 | View on chart |
| HUMA | ▲ Buy | Option Exercise | 39,389 | $101K | 6/14/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Humacyte Adds Scott Coward and Paul Kuznik to Board
Humacyte added Scott Coward and Paul Kuznik to its board, expanding expertise in regulatory and clinical areas. The move comes as the stock fell 4% in a broader market rally, reflecting short‑term price pressure rather than a change in fundamentals. The new directors bring experience that could support the company’s tissue engineering pipeline, but the current price remains below the 52‑week low.
Humacyte Adds Scott Coward and Paul Kuznik to Board. Humacyte added Scott Coward and Paul Kuznik to its board, expanding expertise in regulatory and clinical areas. The move comes as the stock fell 4% in a broader market rally, reflecting short‑term price pressure rather than a change in fundamentals. The new directors bring experience that could support the company’s tissue engineering pipeline, but the current price remains below the 52‑week low.